Intellia Therapeutics (NTLA) Shares Outstanding (Diluted Average) (2020 - 2026)

Intellia Therapeutics (NTLA) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $118.5 million in Q1 2026.

• Quarterly Shares Outstanding (Diluted Average) rose 14.48% year-over-year to $118.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.5 million (up 14.48% YoY) and the FY2025 annual result came in at $108.4 million, up 9.64% from the prior year.
• Shares Outstanding (Diluted Average) rose to $118.5 million in Q1 2026 per NTLA's latest filing, from $108.4 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $118.5 million in Q1 2026 and bottomed at $74.8 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $95.5 million (2024), against an average of $93.2 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Diluted Average) gained 3.18%; it then rose 17.42% in 2023.
• Tracing NTLA's Shares Outstanding (Diluted Average) over 5 years: stood at $77.0 million in 2022, then grew by 15.33% to $88.8 million in 2023, then advanced by 11.35% to $98.8 million in 2024, then increased by 9.64% to $108.4 million in 2025, then climbed by 9.33% to $118.5 million in 2026.
• Per Business Quant, the three latest NTLA Shares Outstanding (Diluted Average) figures stand at $118.5 million (Q1 2026), $108.4 million (Q4 2025), and $105.8 million (Q3 2025).

Peer Comparison